림프종

425개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved425 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleInstituto de Investigación Hosp…Phase 1

Autologous CD19/CD22 CAR T cells (Autologous CD19/CD22 CAR T cells)

Precursor Cell Lymphoblastic Leukemia-Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 30Status Recruiting
CGTLimited DatastaleKara Lynn DavisPhase 1

Autologous CD22 CAR T (Autologous CD22 CAR T)

B Cell Lymphoma; Acute Lymphoblastic Leukemia, Pediatric · CD22

#CD22#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 30Status Active
CGTLimited DatastaleYake Biotechnology Ltd.Phase 2

CAR-T cells targeting CD19 and CD22 (CAR-T cells targeting CD19 and CD22)

B-Cell Acute Lymphoblastic Leukemia, Adult · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 30Status Active
AntibodyLimited DatastaleAlliance for Clinical Trials in…Phase 2

Epratuzumab (Epratuzumab)

Lymphoma · Leukemia

#Leukemia#Antibody#Phase2#monoclonal-antibody#Lymphoma+1
Trials 30Status Discontinued
AntibodyLimited DatastaleGrupo Español de Linfomas y Tra…Phase 2

Zevalin (Ibritumomab Tiuxetan, Ibritumomab Tiuxetan (Zevalin))

Non-Hodgkin Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#monoclonal-antibody#Non-HodgkinLymphoma+1
Trials 30Status Active
AntibodyLimited DatastaleADC TherapeuticsPhase 3

Loncastuximab tesirine (Loncastuximab tesirine)

Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Grade 3b Follicular Lymphoma · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#monoclonal-antibody#RecurrentDiffuseLargeB-CellLymph+2
Trials 30Status Recruiting
AntibodyLimited DatastaleJohn ReneauPhase 1

Mogamulizumab (Mogamulizumab)

Recurrent Adult T-Cell Leukemia/Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma · Cutaneous T Cell Lymphoma

#CutaneousTCellLymphoma#Antibody#Phase1#monoclonal-antibody#RecurrentAdultT-CellLeukemia+3
Trials 30Status Recruiting
AntibodyLimited DatastaleTG Therapeutics, Inc.Phase 2

Ublituximab (Ublituximab)

Non-Hodgkins Lymphoma; B-cell Lymphoma · B-Cell Lymphoma

#B-CellLymphoma#Antibody#Phase2#monoclonal-antibody#Non-HodgkinsLymphoma+2
Trials 30Status Active
CGTLimited DatastaleKara Yakhteh Tajhiz Azma CompanyPhase 2

anti-CD19 CAR T cell therapy (anti-CD19 CAR T cell therapy)

Relapse/Refractory B-cell Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 30Status Recruiting
CGTLimited DatastaleNanjing IASO Biotechnology Co.,…Preclinical

chimeric antigen receptor gene modified T cells (chimeric antigen receptor gene modified T cells)

Lymphoma, B-Cell · CD30

#CD30#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 30Status Recruiting
AntibodyLimited DatastaleMarcela V. Maus, M.D.,Ph.D.Phase 2

Emapalumab (Emapalumab)

Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#LargeB-cellLymphoma+2
Trials 29Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 2

TDxD (Fam-Trastuzumab Deruxtecan-Nxki, Fam-Trastuzumab Deruxtecan-Nxki (TDxD))

Gastric Cancer; Gastrointestinal Cancer · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#antibody-drug-conjugate#GastricCancer+2
Trials 27Status Recruiting
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Consolidation with Brentuximab Vedotin)

Hodgkin Lymphoma, Adult · Hodgkin Lymphoma, Adult

#HodgkinLymphomaAdult#ADC#Phase2#antibody-drug-conjugate#HodgkinLymphoma+2
Trials 25Status Recruiting
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin - induction)

Refractory Peripheral T-Cell Lymphoma; Relapsed Peripheral T-Cell Lymphoma · FRα

#FR#ADC#Phase2#antibody-drug-conjugate#RefractoryPeripheralT-CellLympho+2
Trials 24Status Active
CGTLimited DatastaleCelgenePhase 3

JCAR017 (JCAR017)

Lymphoma, Non-Hodgkin · Precursor Cell Lymphoblastic Leukemia-Ly

#PrecursorCellLymphoblasticLeukem#CGT#Phase3#cell-gene-therapy#CAR-T+4
Trials 20Status Active
AntibodyCurated CorestaleRegeneron PharmaceuticalsPhase 3

Odronextamab (Odronextamab)

Relapsed/Refractory Aggressive B-Cell Lymphoma · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#BioJungboMoa-pick#monoclonal-antibody+3
Trials 18Status Recruiting
AntibodyLimited DatastaleKite, A Gilead CompanyPhase 1

Utomilumab (Utomilumab)

Relapsed/Refractory Large B-cell Lymphoma · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#Relapsed+2
Trials 17Status Active
AntibodyLimited DatastaleRochePhase 2

90Yttrium-Ibritumomab Tiuxetan (Zevalin®, 90Yttrium-Ibritumomab Tiuxetan, 90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab)

Follicular Lymphoma · Follicular Lymphoma

#FollicularLymphoma#Antibody#Phase2#monoclonal-antibody#Roche
Trials 16Status Active
CGTLimited DatastaleBeam Therapeutics Inc.Phase 1

BEAM-201 (Allogeneic anti-CD7 CAR-T cells, Allogeneic anti-CD7 CAR-T cells (BEAM-201))

T-Cell Acute Lymphoblastic Leukemia/Lymphoma · T-Cell Acute Lymphoblastic Leukemia/Lymp

#T-CellAcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 16Status Recruiting
CGTLimited DatastaleLiping DouPhase 2

CD22/CD19 Dual-Target CAR-T Cells (CD22/CD19 Dual-Target CAR-T Cells)

B-cell Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 15Status Recruiting

4 / 22 pages

← PreviousNext →